Nuno Mendonça
Chief Tech/Sci/R&D Officer at AC IMMUNE SA
Net worth: 18 835 $ as of 29/04/2024
Nuno Mendonça active positions
| Companies | Position | Start | End |
|---|---|---|---|
| AC IMMUNE SA | Chief Tech/Sci/R&D Officer | 30/09/2023 | - |
Career history of Nuno Mendonça
Former positions of Nuno Mendonça
| Companies | Position | Start | End |
|---|---|---|---|
| AVEXIS INC | Chief Tech/Sci/R&D Officer | - | - |
Training of Nuno Mendonça
| University of Coimbra | Doctorate Degree |
Statistics
International
| Switzerland | 2 |
| United States | 2 |
| Portugal | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Private companies | 1 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
- Stock Market
- Insiders
- Nuno Mendonça
- Experience
